Fate Therapeutics Inc (NASDAQ: FATE) on Monday, soared 5.79% from the previous trading day, before settling in for the closing price of $2.42. Within the past 52 weeks, FATE’s price has moved between $1.91 and $8.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 87.14% over the last five years. The company achieved an average annual earnings per share of -0.05%. With a float of $98.13 million, this company’s outstanding shares have now reached $98.63 million.
The firm has a total of 181 workers. Let’s measure their productivity. In terms of profitability, gross margin is -55.61%, operating margin of -1587.28%, and the pretax margin is -1426.67%.
Fate Therapeutics Inc (FATE) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Fate Therapeutics Inc is 13.83%, while institutional ownership is 93.37%. The most recent insider transaction that took place on Aug 06 ’24, was worth 2,678. In this transaction Director of this company sold 633 shares at a rate of $4.23, taking the stock ownership to the 8,669 shares. Before that another transaction happened on Aug 06 ’24, when Company’s Director proposed sale 633 for $4.23, making the entire transaction worth $2,678.
Fate Therapeutics Inc (FATE) Earnings and Forecasts
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.46 earnings per share (EPS) for the period topping the consensus outlook (set at -0.57) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.05% per share during the next fiscal year.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Fate Therapeutics Inc (FATE) is currently performing well based on its current performance indicators. A quick ratio of 9.18 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.71, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.65 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Analysing the last 5-days average volume posted by the [Fate Therapeutics Inc, FATE], we can find that recorded value of 1.52 million was lower than the volume posted last year of 2.18 million. As of the previous 9 days, the stock’s Stochastic %D was 38.71%. Additionally, its Average True Range was 0.24.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 7.95%, which indicates a significant decrease from 30.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 104.41% in the past 14 days, which was higher than the 86.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.22, while its 200-day Moving Average is $4.56. Now, the first resistance to watch is $2.63. This is followed by the second major resistance level at $2.71. The third major resistance level sits at $2.84. If the price goes on to break the first support level at $2.43, it is likely to go to the next support level at $2.30. Should the price break the second support level, the third support level stands at $2.23.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
Market capitalization of the company is 276.66 million based on 113,878K outstanding shares. Right now, sales total 63,530 K and income totals -160,930 K. The company made 6,770 K in profit during its latest quarter, and -38,430 K in sales during its previous quarter.
